bpc-157 phase ii ulcerative colitis Left, 14 days) (right, 28 days). Transected muscle and BPC 157 therapy BioWorld

LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al

Use a U-100 insulin syringe for precision 0.25mL equals 25 units, 0.5mL equals 50 units

Central nervous system effects may play a role in altered taste experiences

Fagelman is not only my primary physician but a friend

Toxicity: Not tested for human safety